Moderna, Inc.

( )
MRNA PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 3.15%454.600.0%$6127.57m
BNTXBioNTech SE 4.05%352.990.0%$1059.79m
NVAXNovavax, Inc. 10.90%257.3079.4%$994.94m
SNSSSunesis Pharmaceuticals, Inc. 2.00%8.690.7%$607.46m
AMGNAmgen, Inc. 0.66%215.051.4%$556.80m
GILDGilead Sciences, Inc. 0.43%71.691.0%$457.92m
REGNRegeneron Pharmaceuticals, Inc. -0.09%646.512.7%$422.03m
TECHBio-Techne Corp. 0.73%536.904.5%$370.97m
ILMNIllumina, Inc. -0.32%433.203.5%$350.21m
BIIBBiogen, Inc. 1.34%293.201.7%$310.59m
VRTXVertex Pharmaceuticals, Inc. 0.45%185.091.9%$247.51m
ISEEIVERIC bio, Inc. 1.44%16.230.0%$190.62m
LIFEaTyr Pharma, Inc. 8.33%12.482.1%$188.70m
DVAXDynavax Technologies Corp. 4.31%19.605.7%$160.10m
BGNEBeiGene Ltd. -0.71%385.421.3%$145.35m

Company Profile

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.